MEDIAN Technologies SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0011049824
EUR
4.30
2.19 (104.28%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

128.47 k

Shareholding (Dec 2023)

FII

0.18%

Held by 1 FIIs

DII

99.82%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 163 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.82

stock-summary
Return on Equity

56.66%

stock-summary
Price to Book

-4.02

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
53.02%
0%
53.02%
6 Months
23.92%
0%
23.92%
1 Year
40.98%
0%
40.98%
2 Years
-20.66%
0%
-20.66%
3 Years
-66.41%
0%
-66.41%
4 Years
-64.52%
0%
-64.52%
5 Years
-7.33%
0%
-7.33%

MEDIAN Technologies SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
16.48%
EBIT Growth (5y)
-175.51%
EBIT to Interest (avg)
-9.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
-0.95
Tax Ratio
0.57%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.18%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.49
EV to EBIT
-11.68
EV to EBITDA
-13.14
EV to Capital Employed
-29.26
EV to Sales
9.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by MEDIAN Technologies SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.15% vs -6.33% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -9.57% vs -13.86% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22.90",
          "val2": "22.20",
          "chgp": "3.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.50",
          "val2": "-21.80",
          "chgp": "5.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.00",
          "val2": "2.10",
          "chgp": "90.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.00",
          "val2": "2.20",
          "chgp": "-54.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.20",
          "val2": "-23.00",
          "chgp": "-9.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-977.40%",
          "val2": "-1,035.10%",
          "chgp": "5.77%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
22.90
22.20
3.15%
Operating Profit (PBDIT) excl Other Income
-20.50
-21.80
5.96%
Interest
4.00
2.10
90.48%
Exceptional Items
1.00
2.20
-54.55%
Consolidate Net Profit
-25.20
-23.00
-9.57%
Operating Profit Margin (Excl OI)
-977.40%
-1,035.10%
5.77%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 3.15% vs -6.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -9.57% vs -13.86% in Dec 2023

stock-summaryCompany CV
About MEDIAN Technologies SA stock-summary
stock-summary
MEDIAN Technologies SA
Pharmaceuticals & Biotechnology
Median Technologies SA is a France-based company that publishes software for the diagnosis and monitoring of cancer patients. The Company develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The Company operates one subsidiary, Median Technologies Inc, based in the United States.
Company Coordinates stock-summary
Company Details
Les Deux Arcs B, 1800 route des Cretes , VALBONNE None : 06560
Registrar Details